HC Wainwright Forecasts Higher Earnings for Editas Medicine

Editas Medicine, Inc. (NASDAQ:EDIT) – HC Wainwright boosted their FY2026 EPS estimates for shares of Editas Medicine in a report released on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.61) per share for the year, up from their prior forecast of ($0.66). The consensus estimate for Editas Medicine’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Editas Medicine’s Q1 2027 earnings at ($0.21) EPS and Q2 2027 earnings at ($0.22) EPS.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. The company had revenue of $10.37 million for the quarter, compared to analyst estimates of $4.46 million. Editas Medicine had a negative net margin of 144.95% and a negative return on equity of 130.43%.

Several other research firms have also recently commented on EDIT. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Wells Fargo & Company upgraded Editas Medicine from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $4.00 to $6.00 in a research report on Thursday, October 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Editas Medicine in a research note on Wednesday, November 4th. Guggenheim raised Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Wednesday, September 23rd. Finally, Ladenburg Thalmann & Co. Inc. initiated coverage on Editas Medicine in a report on Tuesday, August 18th. They set a “buy” rating and a $6.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $5.83.

Editas Medicine Trading Down 5.2%

Shares of NASDAQ EDIT opened at $2.38 on Thursday. The stock has a 50 day simple moving average of $2.67 and a 200-day simple moving average of $2.69. Editas Medicine has a 12-month low of $1.66 and a 12-month high of $3.94.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Editas Medicine during the second quarter worth approximately $34,312,000. ADAR1 Capital Management LLC bought a new position in Editas Medicine during the 2nd quarter valued at $28,800,000. State Street Corp boosted its stake in Editas Medicine by 60.6% during the 3rd quarter. State Street Corp now owns 7,038,580 shares of the company’s stock valued at $18,089,000 after purchasing an additional 2,654,974 shares in the last quarter. Opaleye Management Inc. boosted its stake in Editas Medicine by 100.4% during the 2nd quarter. Opaleye Management Inc. now owns 3,861,930 shares of the company’s stock valued at $12,513,000 after purchasing an additional 1,934,933 shares in the last quarter. Finally, Seven Fleet Capital Management LP bought a new position in Editas Medicine during the 2nd quarter valued at $4,310,820. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc. is a biotechnology company developing genome-editing medicines for people with serious diseases. Its research uses CRISPR-based technologies, including CRISPR-Cas9 and Cas12a, to make targeted changes to DNA. Founded in 2013 and based in Cambridge, Massachusetts, the company conducts research and clinical development of potential treatments for genetic disorders. Its work has included approaches designed to edit genes in a patient’s cells, either outside the body or directly within the body.